Replies to post #55602 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Love the title -

A unique target for a comprehensive therapy of Alzheimer’s disease: concomitant activation of SIGMA1/M1 muscarinic receptors

No other company could use those terms for an AZ drug...

[TrueTrades]

That is the study done by Dr Fisher et al in 2013 which he lectured about in 2014:

http://www.anavex.com/?news=anavex-3-71-highly-effective-and-disease-modifying-against-all-major-alzheimers-hallmarks-in-preclinical-disease-model

http://www.anavex.com/files/AbstractBook__WEB2014_2_Pages.pdf

http://www.anavex.com/pdf/2014-07-13_Fisher_Abstract_for_AAIC_meeting_2014.pdf

The data being presented next week is a study done at McGill U. last year...I believe?

33. Hélène Hall, M. Florencia Iulita, Adriana Ducatenzeiler, Abraham Fisher, A. Claudio Cuello
[Category: Pre-clinical Trials]
AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible diseasemodifying
properties in McGill-R-Thy1-APP rats

Went to check the program and notice the 12:20 - 12:40 slot for Anavex is not listed? WTF?
http://www.siumed.edu/cpd/alzheimer/program.html

"12:20 – 13:45 Lunch and informal networking with the experts"

The pdf program still has it listed:
http://www.siumed.edu/cpd/alzheimer/pdf/Program_2016.pdf

Xena: The run up was organic. I was there, trading every day. It was the 10MM naked shares used the week of Nov 9 that did the damage.
§